Fintel reports that on April 15, 2024, Guggenheim initiated coverage of enGene Holdings (NasdaqCM:ENGN) with a Buy recommendation.
Analyst Price Forecast Suggests 132.55% Upside
As of March 31, 2024, the average one-year price target for enGene Holdings is 36.72. The forecasts range from a low of 31.31 to a high of $42.00. The average price target represents an increase of 132.55% from its latest reported closing price of 15.79.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for enGene Holdings is 0MM. The projected annual non-GAAP EPS is -1.10.
What is the Fund Sentiment?
There are 20 funds or institutions reporting positions in enGene Holdings. This is an increase of 11 owner(s) or 122.22% in the last quarter.
What are Other Shareholders Doing?
Fcpm Iii Services B.v. holds 8,678K shares representing 19.91% ownership of the company.
Bvf holds 2,251K shares representing 5.17% ownership of the company.
Blue Owl Capital Holdings holds 1,235K shares representing 2.83% ownership of the company.
Omega Fund Management holds 1,131K shares representing 2.60% ownership of the company.
Vivo Capital holds 679K shares representing 1.56% ownership of the company.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
